Trial Watch: Peptide vaccines in cancer therapy

Keyphrases

• Adaptive Immune Response 25%
• Anticancer Agents 50%
• Anticancer Vaccines 100%
• Antigen-specific Immunity 25%
• Antineoplastic Agents 25%
• Biological Mechanisms 25%
• Cancer Therapy 100%
• Cell-based 25%
• Clinical Potential 25%
• Clinical Trials 25%
• Component-based 25%
• DNA Sequencing 25%
• High Profile 25%
• Immune Checkpoint 25%
• Immune Response 25%
• Immune System 25%
• Immunogenic 25%
• Immunological Tolerance 25%
• Immunosuppressive Cytokines 25%
• In Cancer 100%
• Innate Immune Response 25%
• Late Development 25%
• Malignant Cells 25%
• Neoplastic Lesions 25%
• Oncogenesis 25%
• Oncoimmunology 25%
• Peptide Vaccine 100%
• Profile Study 25%
• Prophylactic Treatment 25%
• Purified Peptide 25%
• Receptor Agonist 25%
• Receptor Antagonist 25%
• Toll-like 25%
• Tumor 25%
• Tumor Antigen 25%
• Tumor Progression 25%

Immunology and Microbiology

• Adaptive Immune System 100%
• Adjuvant 50%
• Agonist 50%
• Cytokine 50%
• Immune Response 50%
• Immune System 50%
• Immune Tolerance 50%
• Immunity 50%
• Immunosuppressive Drug 50%
• Innate Immune System 50%
• Peptide Vaccine 100%
• Toll-Like Receptor 50%
• Tumor Antigen 50%

Biochemistry, Genetics and Molecular Biology

• Adaptive Immunity 33%
• Anticancer 100%
• Carcinogenesis 16%
• Clinical Trial 16%
• Cytokine 16%
• Immune Checkpoints 16%
• Immune Response 16%
• Immunity 16%
• Immunological Tolerance 16%
• Innate Immunity 16%
• Receptor Agonists 16%
• Toll-Like Receptor 16%
• Tumor Antigen 16%
• Tumor Progression 16%
• Vaccine Peptide 100%